Karin Rodland

Dr. Karin Rodland’s many achievements include her decades long commitment to the application of cutting-edge mass spectrometry technologies to compelling biological problems. She has provided biological focus to the proteomics group at PNNL since 2002, insuring that the technologies were applied to the most significant biomedical problems and that issues of experimental design and data analysis reflected the needs of the biomedical community. Dr. Rodland has published extensively in the field of proteomics, on the use of mass spectrometry to further understanding of basic biological processes. She was among the first to characterize the role of the G-protein coupled calcium-sensing receptor in modulating proliferation-associated signal transduction pathways. However, her impact can be better quantified in terms of her unique ability to establish collaborations that bring cutting-edge proteomics technologies into the translational cancer medicine space through the application of proteogenomics to understand drug response and therapeutic resistance.